Resumé
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | HIV Medicine |
| Vol/bind | 9 |
| Udgave nummer | 5 |
| Sider (fra-til) | 300-306 |
| Antal sider | 6 |
| ISSN | 1464-2662 |
| DOI | |
| Status | Udgivet - 1. maj 2008 |
Fingeraftryk
Citer dette
}
Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals : a nationwide cohort study. / Omland, L H; Weis, N; Skinhøj, P; Laursen, Alex; Christensen, Peer Brehm; Nielsen, H I; Møller, Axel; Engsig, F; Sørensen, Henrik Toft; Obel, N.
I: HIV Medicine, Bind 9, Nr. 5, 01.05.2008, s. 300-306.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
TY - JOUR
T1 - Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals
T2 - a nationwide cohort study
AU - Omland, L H
AU - Weis, N
AU - Skinhøj, P
AU - Laursen, Alex
AU - Christensen, Peer Brehm
AU - Nielsen, H I
AU - Møller, Axel
AU - Engsig, F
AU - Sørensen, Henrik Toft
AU - Obel, N
PY - 2008/5/1
Y1 - 2008/5/1
N2 - BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infected patients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6%), HBV-negative (87%) or HBV-unknown (7%). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6%). Study endpoints were viral load, CD4 cell count and mortality. RESULTS: HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95% confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95% CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95% CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIV patients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infected patients have an increased mortality compared to HIV-monoinfected patients.
AB - BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infected patients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6%), HBV-negative (87%) or HBV-unknown (7%). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6%). Study endpoints were viral load, CD4 cell count and mortality. RESULTS: HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95% confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95% CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95% CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIV patients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infected patients have an increased mortality compared to HIV-monoinfected patients.
U2 - 10.1111/j.1468-1293.2008.00564.x
DO - 10.1111/j.1468-1293.2008.00564.x
M3 - Journal article
VL - 9
SP - 300
EP - 306
JO - HIV Medicine
JF - HIV Medicine
SN - 1464-2662
IS - 5
ER -